Leukemia

Article	Citations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms	1479
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	1267
MDM2 inhibition: an important step forward in cancer therapy	218
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	190
Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?	176
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis	171
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	160
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances	157
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	139
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies	116
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	115
Molecular biology of Hodgkin lymphoma	115
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis	115
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma	104
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms	99
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk	98
Advances in understanding of angioimmunoblastic T-cell lymphoma	96
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network	85
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia	80
Catch me if you can: how AML and its niche escape immunotherapy	80
Therapeutic implications of menin inhibition in acute leukemias	80
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia	77
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	76
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML	76
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials	75

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In	73
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia	72
Base-edited CAR T cells for combinational therapy against T cell malignancies	68
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma	68
NK-/T-cell lymphomas	67
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib	66
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape	66
Genome instability in multiple myeloma	65
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia	63
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells	61
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	60
The WHO Classification of Haematolymphoid Tumours	60
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views	60
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study	60
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network	60
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	60
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges	59
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival	57
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	56
Current challenges and unmet medical needs in myelodysplastic syndromes	55
Treatment resistance in diffuse large B-cell lymphoma	55
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial	55
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner	55
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma	54
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial	54
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)	54
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	53
New strategies to treat AML: novel insights into AML survival pathways and combination therapies	52
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA	51
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease	51
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial	50
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations	50
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia	49
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis	49
Decrease post-transplant relapse using donor-derived expanded NK-cells	49
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion	49
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma	48
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States	48
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions	47
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631	46
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant	46
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression	46
Second cancer incidence in CLL patients receiving BTK inhibitors	45
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial	45
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter	45
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma	45
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT	45
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results	44
Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy	44
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b	44

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	44
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia	43
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML	43
Germline variants drive myelodysplastic syndrome in young adults	43
Folate metabolism: a re-emerging therapeutic target in haematological cancers	43
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations	43
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL	42
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study	42
Targeting nuclear import and export in hematological malignancies	42
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)	42
The KMT2A recombinome of acute leukemias in 2023	42
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears	41
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia	41
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma	41
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of th	41
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations	40
Complex landscape of alternative splicing in myeloid neoplasms	40
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group	39
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial	39
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib	39
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results	39
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial	39
The mutagenic impact of melphalan in multiple myeloma	38
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	38
Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy	37
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views	37
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas	37
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms	36
Imatinib is not a potent anti-SARS-CoV-2 drug	36
Two decades of targeted therapies in acute myeloid leukemia	36
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection	36
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse	35
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia	35
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19	35
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms	35
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis	35
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma	34
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer	34
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia	34
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome	34
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets	33
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE	33
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma	33
Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells	32
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients	32
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis	32
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses	32
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma	32
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma	32
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis	31
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease	31
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia	31
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy	30
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma	30
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study	30
Current status and future perspectives in targeted therapy of NPM1-mutated AML	30
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis	30
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators	30
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia	29
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia	29
Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission	29
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance	29
Selective elimination of immunosuppressive T cells in patients with multiple myeloma	29
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling	29
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research	28
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic l	28
Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma	28
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	28
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries	27
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies	27
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy	27
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia	27
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells	27
KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements	27
Hematopoietic stem and progenitor cell signaling in the niche	27
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial	27
METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	27
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo	27
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study	27
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence	27

Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients	27
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia	27
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas	27
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study	26
SARS-CoV-2 antibody responses in patients with acute leukaemia	26
Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?	26
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)	26
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	26
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial	26
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	26
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis	26
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines	26
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression	26
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL	26
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia	26
Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	26
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	25
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma	25
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1	25
Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015	25
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients	25
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	25
Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic	25
Clonal hematopoiesis and its emerging effects on cellular therapies	24
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death	24
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)	24
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting	24
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	24
APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations	24
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial	24
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia	24
Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia	24
TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways	24
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation	23
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia	23
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia	23
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia	23
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML	23
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis	23
GSK-3: a multifaceted player in acute leukemias	23
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration	23
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data	23
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity	23
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia	23
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia	23
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	22
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia	22
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms	22
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease	22
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas	22
Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition	22
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells	22
DPP4+ exosomes in AML patients’ plasma suppress proliferation of hematopoietic progenitor cells	22
U2af1 is required for survival and function of hematopoietic stem/progenitor cells	22
PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression	22
High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)	22
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients	22
Lysosomes in acute myeloid leukemia: potential therapeutic targets?	22
A modular and controllable T cell therapy platform for acute myeloid leukemia	22
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field	22
Ethnic and geographic diversity of chronic lymphocytic leukaemia	22
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European	22
Metabolic alterations mediated by STAT3 promotes drug persistence in CML	22
Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism	21
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations	21
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease	21
RNA methylation in hematological malignancies and its interactions with other epigenetic modifications	21
JunB is a key regulator of multiple myeloma bone marrow angiogenesis	21
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review	21
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia	21
The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis	21
Clinical and biological aspects of myeloid leukemia in Down syndrome	21
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?	21
Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin	21
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice	21
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma	21
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study	20
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity	20
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	20
Molecular profiling of EBV associated diffuse large B-cell lymphoma	20
Biological drivers of clinical phenotype in myelofibrosis	20
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML	20
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia	20
RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia	20
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML	20
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia	20
Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis	20
Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma	19
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy	19
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update	19
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma	19
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma	19
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	19
SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2	19
Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship	19